BRAF and neoplasm: The BRAF mutation drives the tumor proliferation exponentially by activating mitogen-activated kinase pathway (MAP), and the development of resistance to BRAF inhibitors in both MAP kinase-dependent and MAP kinase-independent pathways (65-67).